Omega-3 (n-3) polyunsaturated fatty acids (PUFA) and fluoxetine (FLX) have additive effects in the treatment of major depressive disorder, and FLX up-regulates genes that regulate fatty acid biosynthesis in vitro. Although these data suggest that FLX may augment n-3 fatty acid biosynthesis, the in vivo effects of FLX treatment on PUFA biosynthesis and peripheral and central membrane compositions are not known. In the present study, male and female rats were treated with FLX (10 mg/kg/day) through their drinking water for 30 days (P60-P90). Plasma FLX and norfluoxetine (NFLX) concentrations were determined by liquid chromatography tandem mass spectrometry, and erythrocyte and prefrontal cortex (PFC) fatty acid composition determined by gas chromatography. To confirm central effects of FLX, serotonin turnover in the PFC was determined by high performance liquid chromatography. Chronic FLX treatment resulted in clinically-relevant plasma FLX concentrations in male and female rats, and significantly decreased serotonin turnover in the PFC. After correcting for multiple comparisons, chronic FLX treatment did not significantly alter erythrocyte fatty acid composition in male or female rats. Chronic FLX treatment significantly and selectively increased docosapentaenoic acid (22:5n-6) in the PFC of female rats, but not in male rats. These preclinical findings do not support the hypothesis that chronic FLX treatment increases n-3 fatty acid biosynthesis or membrane composition.
Introduction
Several lines of evidence suggest that major depressive disorder (MDD) is associated with a dysregulation in polyunsaturated fatty acid (PUFA) homeostasis (McNamara, 2008) . For example, crosssectional studies have observed significant omega-3 (n-3) fatty acid deficits in erythrocytes (Edwards et al., 1998; McNamara et al., 2010; Peet et al., 1998) and postmortem prefrontal cortex (PFC) (McNamara et al., 2007) of MDD patients. Moreover, controlled intervention trials have found that dietary n-3 fatty acid supplementation has a significant advantage over placebo for reducing depression symptom severity in predominantly medicated MDD patients (Freeman et al., 2006; Lin and Su, 2007) . A recent controlled trial found that combining n-3 fatty acids and fluoxetine (FLX) had additive effects for reducing depression symptom severity in MDD patients (Jazayeri et al., 2008) . Moreover, preclinical studies have found that FLX and n-3 fatty acids both reduce behavioral indices of depression in rats (Carlezon et al., 2005) . However, it is not known whether the antidepressant effects of FLX and long-chain n-3 fatty acids are mediated by common or divergent mechanisms.
One candidate mechanism by which FLX may exert therapeutic efficacy is through the augmentation of long-chain n-3 fatty acid biosynthesis and subsequent membrane composition. This is supported in part by an in vitro study finding that chronic exposure to antidepressant medications including FLX up-regulate sterol regulatory element-binding protein (SREBP) (Raeder et al., 2006) , and SREBP positively regulates the expression of the principal genes that regulate PUFA biosynthesis, delta-5 desaturase (FADS1) and delta-6 desaturase (FADS2) (Matsuzaka et al., 2002) . Moreover, antipsychotic medications also up-regulate SREBP and FADS1 and FADS2 expressions (Fernø et al., 2005; Polymeropoulos et al., 2009) , and significantly increased rat erythrocyte and PFC n-3 fatty acid composition (McNamara et al., 2009a) . Chronic FLX treatment was also found to increase incorporation of the long-chain n-6 fatty acid [ Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; AA, arachidonic acid; cPLA 2 , cytosolic phospholipase A 2 ; DHA, docosahexaenoic acid; FLX, fluoxetine; MDD, major depressive disorder; n-3, omega-3; NFLX, norfluoxetine; PFC, prefrontal cortex; PUFA, polyunsaturated fatty acids; SREBP, sterol regulatory elementbinding protein.
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